PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2023-05-12 (2)

Date Title Company
12-May-2023 Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases Businesswire